The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18.

TY - JOUR

T1 - The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18.

AU - Laigaard, Jennie

AU - Christiansen, Michael

AU - Frohlich, Camilla

AU - Pedersen, Bent Nøorgaard

AU - Ottesen, Bent

AU - Wewer, Ulla M

N1 - Keywords: ADAM Proteins; Adult; Biological Markers; Chromosomes, Human, Pair 18; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Female; Humans; Membrane Proteins; Metalloendopeptidases; Pregnancy; Pregnancy Trimester, First; Prenatal Diagnosis; Retrospective Studies; Trisomy

PY - 2005

Y1 - 2005

N2 - BACKGROUND: ADAM12-S is a pregnancy-associated insulin-like growth factor binding protein-3 (IGFBP-3) and IGFBP-5 protease present in human gestational serum. Recently, maternal serum levels of ADAM12-S were found to be markedly reduced during the first trimester of pregnancies with a Down syndrome (DS) fetus. On the basis of this finding, it was suggested that ADAM12-S might be a useful maternal serum marker of fetal chromosomal disease. OBJECTIVE: Retrospective examination of the use of ADAM12-S as a marker for fetal trisomy 18. METHOD: Serum samples were obtained from ten women during the first semester of their pregnancies with fetuses that had trisomy 18. An ELISA was used to determine the levels of ADAM12 in maternal serum. Results were compared to ADAM12-S levels, previously measured in the serum of 170 women carrying normal pregnancies during the first trimester. RESULTS: In all cases, the ADAM12-S concentration in maternal serum samples was lower in trisomy 18 pregnancies than in normal pregnancies, with a median multiple of the median (MoM) of 0.28 (p < 0.001) CONCLUSION: A reduced concentration of ADAM12-S in maternal serum is a promising marker for foetal trisomy 18, as well as for DS.

AB - BACKGROUND: ADAM12-S is a pregnancy-associated insulin-like growth factor binding protein-3 (IGFBP-3) and IGFBP-5 protease present in human gestational serum. Recently, maternal serum levels of ADAM12-S were found to be markedly reduced during the first trimester of pregnancies with a Down syndrome (DS) fetus. On the basis of this finding, it was suggested that ADAM12-S might be a useful maternal serum marker of fetal chromosomal disease. OBJECTIVE: Retrospective examination of the use of ADAM12-S as a marker for fetal trisomy 18. METHOD: Serum samples were obtained from ten women during the first semester of their pregnancies with fetuses that had trisomy 18. An ELISA was used to determine the levels of ADAM12 in maternal serum. Results were compared to ADAM12-S levels, previously measured in the serum of 170 women carrying normal pregnancies during the first trimester. RESULTS: In all cases, the ADAM12-S concentration in maternal serum samples was lower in trisomy 18 pregnancies than in normal pregnancies, with a median multiple of the median (MoM) of 0.28 (p < 0.001) CONCLUSION: A reduced concentration of ADAM12-S in maternal serum is a promising marker for foetal trisomy 18, as well as for DS.

U2 - 10.1002/pd.1029

DO - 10.1002/pd.1029

M3 - Journal article

C2 - 15662668

SN - 0197-3851

VL - 25

SP - 45

EP - 46

JO - Prenatal Diagnosis

JF - Prenatal Diagnosis

IS - 1

ER -